MacroGenics Inc (NASDAQ:MGNX)

12.13
BATS BZX Real-Time Price
As of 1:20pm ET
 -0.61 / -4.79%
Today’s Change
11.70
Today|||52-Week Range
36.48
-24.42%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$792.1M

Company Description

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Contact Information

MacroGenics, Inc.
9704 Medical Center Drive
Rockville Maryland 20850-3368
P:(301) 251-5172
Investor Relations:
(301) 354-2681

Employees

Shareholders

Mutual fund holders47.92%
Other institutional44.38%
Individual stakeholders26.10%

Top Executives

Scott E. KoenigPresident, Chief Executive Officer & Director
James KarrelsChief Financial Officer, Secretary & Senior VP
Ezio BonviniChief Scientific Officer & Senior VP-Research
Stephen L. EckChief Medical Officer & SVP-Clinical Development
Lynn CilinskiTreasurer, Vice President & Controller